-
1
-
-
24644453083
-
Transfer of lipophilic drugs between liposomal membranes and biological interfaces: Consequences for drug delivery
-
DOI 10.1016/j.ejps.2005.05.012, PII S0928098705001922
-
Fahr A, van Hoogevest P, May S, et al. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. Eur J Pharm Sci 2005;26:251-65 (Pubitemid 41278632)
-
(2005)
European Journal of Pharmaceutical Sciences
, vol.26
, Issue.3-4
, pp. 251-265
-
-
Fahr, A.1
Hoogevest, P.V.2
May, S.3
Bergstrand, N.4
Leigh, M.L.S.5
-
2
-
-
54349108703
-
-
Commissioner of Food and Drugs Rockville MD 20857
-
Commissioner of Food and Drugs. Nanotechnology Task Force Report, FDA Rockville MD 20857, 2007
-
(2007)
Nanotechnology Task Force Report, FDA
-
-
-
5
-
-
34548484667
-
Nano-based drugs and medical devices: FDA's track record
-
Strickland CH. Nano-based drug and medical devices: FDA track record. Nanotechnol Law Bus 2007;4:179-88 (Pubitemid 47510236)
-
(2007)
Nanotechnology Law and Business
, vol.4
, Issue.2
, pp. 179-188
-
-
Strickland, C.H.1
-
8
-
-
34547864243
-
Drug delivery strategies for poorly water-soluble drugs
-
DOI 10.1517/17425247.4.4.403
-
Fahr A, Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv 2007;4:403-16 (Pubitemid 47249138)
-
(2007)
Expert Opinion on Drug Delivery
, vol.4
, Issue.4
, pp. 403-416
-
-
Fahr, A.1
Liu, X.2
-
9
-
-
1842689072
-
Pharmaceutical evaluation of early development candidates "the 100 mg-approach"
-
DOI 10.1016/j.ijpharm.2004.01.034, PII S0378517304000699
-
Balbach S, Korn C. Pharmaceutical evaluation of early development candidates "the 100 mg-approach". Int J Pharm 2004;275:1-12 (Pubitemid 38481515)
-
(2004)
International Journal of Pharmaceutics
, vol.275
, Issue.1-2
, pp. 1-12
-
-
Balbach, S.1
Korn, C.2
-
10
-
-
77956609919
-
Development and application of a high throughput screening for oral administration in drug discovery
-
Gopinathan S, Noraldeen A, Wilson AGE. Development and application of a high throughput screening for oral administration in drug discovery. Future Med Chem 2010;2:1392-8
-
(2010)
Future Med Chem
, vol.2
, pp. 1392-8
-
-
Gopinathan, S.1
Noraldeen, A.2
Wilson, A.G.E.3
-
11
-
-
77249111754
-
Porous carriers for controlled/modulated drug delivery
-
Ahuja G, Pathak K. Porous carriers for controlled/modulated drug delivery. Indian J Pharm Sci 2009;71:599-607
-
(2009)
Indian J Pharm Sci
, vol.71
, pp. 599-607
-
-
Ahuja, G.1
Pathak, K.2
-
13
-
-
51249101525
-
Nanocrystalline pharmaceutical patent litigation the first case
-
Prendergast WF, Schafer HN. Nanocrystalline pharmaceutical patent litigation: the first case. Nanotechnol Law Bus 2008;5:157-61
-
(2008)
Nanotechnol Law Bus
, vol.5
, pp. 157-61
-
-
Prendergast, W.F.1
Schafer, H.N.2
-
15
-
-
0022404616
-
Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog
-
DOI 10.1007/BF01983649
-
Masini E, Planchenault J, Pezziardi F, et al. Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog. Agents Actions 1985;16:470-7 (Pubitemid 16220968)
-
(1985)
Agents and Actions
, vol.16
, Issue.6
, pp. 470-477
-
-
Masini, E.1
Planchenault, J.2
Pezziardi, F.3
-
17
-
-
0023948933
-
Study of histamine release induced by acute administration of antitumor agents in dogs
-
Eschalier A, Lavarenne J, Burtin C, et al. Study of histamine release induced by acute administration of antitumor agents in dogs. Cancer Chemother Pharmacol 1988;21:246-50
-
(1988)
Cancer Chemother Pharmacol
, vol.21
, pp. 246-50
-
-
Eschalier, A.1
Lavarenne, J.2
Burtin, C.3
-
19
-
-
0022615494
-
Modulation of histamine release from rat peritoneal mast cells by non-cytotoxic concentrations of the detergents Cremophor El® (oxethylated castor oil) and Triton X100. A possible explanation for unexpected adverse drug reactions?
-
Ennis M, Lorenz W, Gerland W. Modulation of histamine release from rat peritoneal mast cells by non-cytotoxic concentrations of the detergents Cremophor El (oxethylated castor oil) and Triton X100. A possible explanation for unexpected adverse drug reactions? Agents Actions 1986;18:235-8 (Pubitemid 16113264)
-
(1986)
Agents and Actions
, vol.18
, Issue.1-2
, pp. 235-238
-
-
Ennis, M.1
Lorenz, W.2
Gerland, W.3
-
20
-
-
0021955562
-
Comparison of the histamine-releasing activity of cremophor E1® and some of its derivatives in two experimental models: The in vivo anaesthetized dog and in vitro rat peritoneal mast cells
-
DOI 10.1007/BF01983156
-
Ennis M, Lorenz W, Kapp B, et al. Comparison of the histamine-releasing activity of cremophor E1 and some of its derivatives in two experimental models: the in vivo anaesthetized dog and in vitro rat peritoneal mast cells. Agents Actions 1985;16:265-8 (Pubitemid 15116711)
-
(1985)
Agents and Actions
, vol.16
, Issue.3-4
, pp. 265-268
-
-
Ennis, M.1
Lorenz, W.2
Kapp, B.3
-
21
-
-
0017346930
-
Histamine release in dogs by Cremophor E1 and its derivatives: Oxethylated oleic acid is the most effective constituent
-
Lorenz W, Reimann HJ, Schmal A, et al. Histamine release in dogs by Cremophor E1 and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 1977;7:63-7 (Pubitemid 8070781)
-
(1977)
Agents and Actions
, vol.7
, Issue.1
, pp. 63-67
-
-
Lorenz, W.1
Reimann, H.J.2
Schmal, A.3
-
22
-
-
0019997303
-
Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: Analysis of various components in cremophor E1 and development of a compound with reduced toxicity
-
DOI 10.1007/BF01965109
-
Lorenz W, Schmal A, Schult H, et al. Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: analysis of various components in cremophor El and development of a compound with reduced toxicity. Agents Actions 1982;12:64-80 (Pubitemid 12076385)
-
(1982)
Agents and Actions
, vol.12
, Issue.1-2
, pp. 64-80
-
-
Lorenz, W.1
Schmal, A.2
Schult, H.3
-
23
-
-
80054804979
-
Applications of Solutol HS 15
-
Thaysen G. Applications of Solutol HS 15 In: ExAct B; 1999. p. 7
-
(1999)
ExAct B
, pp. 7
-
-
Thaysen, G.1
-
24
-
-
0021688832
-
Preclinical safety evaluation of intravenously administered mixed micelles
-
Teelmann K, Schlappi B, Schupbach M, et al. Preclinical safety evaluation of intravenously administered mixed micelles. Arzneimittelforschung 1984;34:1517-23 (Pubitemid 15203496)
-
(1984)
Arzneimittel-Forschung/Drug Research
, vol.34
, Issue.11
, pp. 1517-1523
-
-
Teelmann, K.1
Schlappi, B.2
Schupbach, M.3
Kistler, A.4
-
25
-
-
1242337285
-
Solubilizing Excipients in Oral and Injectable Formulations
-
DOI 10.1023/B:PHAM.0000016235.32639.23
-
Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004;21:201-30 (Pubitemid 38221966)
-
(2004)
Pharmaceutical Research
, vol.21
, Issue.2
, pp. 201-230
-
-
Strickley, R.G.1
-
26
-
-
33748504537
-
Lipophilic drug transfer between liposomal and biological membranes: What does it mean for parenteral and oral drug delivery?
-
DOI 10.1080/08982100600848702, PII M86505185166M711
-
Fahr A, van Hoogevest P, Kuntsche J, et al. Lipophilic drug transfer between liposomal and biological membranes: what does it mean for parenteral and oral drug delivery? J Liposome Res 2006;16:281-301 (Pubitemid 44359001)
-
(2006)
Journal of Liposome Research
, vol.16
, Issue.3
, pp. 281-301
-
-
Fahr, A.1
Van Hoogevest, P.2
Kuntsche, J.3
Leigh, M.L.S.4
-
27
-
-
39149095938
-
Advanced screening assays to rapidly identify solubility-enhancing formulations: High-throughput, miniaturization and automation
-
Dai WG, Pollock-Dove C, Dong LC, et al. Advanced screening assays to rapidly identify solubility-enhancing formulations: high-throughput, miniaturization and automation. Adv Drug Deliv Rev 2008;60:657-72
-
(2008)
Adv Drug Deliv Rev
, vol.60
, pp. 657-72
-
-
Dai, W.G.1
Pollock-Dove, C.2
Dong, L.C.3
-
28
-
-
34047271049
-
Parallel screening approach to identify solubility-enhancing formulations for improved bioavailability of a poorly water-soluble compound using milligram quantities of material
-
DOI 10.1016/j.ijpharm.2006.11.034, PII S0378517306009768
-
Dai WG, Dong LC, Li S, et al. Parallel screening approach to identify solubility-enhancing formulations for improved bioavailability of a poorly water-soluble compound using milligram quantities of material. Int J Pharm 2007;336:1-11 (Pubitemid 46551550)
-
(2007)
International Journal of Pharmaceutics
, vol.336
, Issue.1
, pp. 1-11
-
-
Dai, W.-G.1
Dong, L.C.2
Li, S.3
Pollock-Dove, C.4
Chen, J.5
Mansky, P.6
Eichenbaum, G.7
-
29
-
-
34250746898
-
Screening method to identify preclinical liquid and semi-solid formulations for low solubility compounds: Miniaturization and automation of solvent casting and dissolution testing
-
DOI 10.1002/jps.20799
-
Mansky P, Dai WG, Li S, et al. Screening method to identify preclinical liquid and semi-solid formulations for low solubility compounds: miniaturization and automation of solvent casting and dissolution testing. J Pharm Sci 2007;96:1548-63 (Pubitemid 46953770)
-
(2007)
Journal of Pharmaceutical Sciences
, vol.96
, Issue.6
, pp. 1548-1563
-
-
Mansky, P.1
Dai, W.-G.2
Li, S.3
Pollock-Dove, C.4
Daehne, K.5
Dong, L.6
Eichenbaum, G.7
-
30
-
-
0037422391
-
An intravenous formulation decision tree for discovery compound formulation development
-
DOI 10.1016/S0378-5173(02)00704-4
-
Lee YC, Zocharski PD, Samas B. An intravenous formulation decision tree for discovery compound formulation development. Int J Pharm 2003;253:111-19 (Pubitemid 36197836)
-
(2003)
International Journal of Pharmaceutics
, vol.253
, Issue.1-2
, pp. 111-119
-
-
Lee, Y.-C.1
Zocharski, P.D.2
Samas, B.3
-
31
-
-
33846290338
-
Preclinical formulations for discovery and toxicology: Physicochemical challenges
-
DOI 10.1517/17425255.2.5.715
-
Neervannan S. Preclinical formulations for discovery and toxicology: physicochemical challenges. Expert Opin Drug MetabToxicol 2006;2:715-31 (Pubitemid 46118317)
-
(2006)
Expert Opinion on Drug Metabolism and Toxicology
, vol.2
, Issue.5
, pp. 715-731
-
-
Neervannan, S.1
-
32
-
-
34447646495
-
Developing early formulations: Practice and perspective
-
DOI 10.1016/j.ijpharm.2007.05.049, PII S0378517307004553
-
Li P, Zhao L. Developing early formulations: practice and perspective. Int J Pharm 2007;341:1-19 (Pubitemid 47088122)
-
(2007)
International Journal of Pharmaceutics
, vol.341
, Issue.1-2
, pp. 1-19
-
-
Li, P.1
Zhao, L.2
-
33
-
-
33847251189
-
Instant solubilization of poorly water-soluble drugs by in-situ loading of aqueous phospholipid dispersions suitable for parenteral administration
-
Van Hoogevest P, Rogue V, Brumec M, et al. Instant solubilization of poorly water-soluble drugs by in-situ loading of aqueous phospholipid dispersions suitable for parenteral administration. PDA J Pharm Sci Technol 2006;60:366-77
-
(2006)
PDA J Pharm Sci Technol
, vol.60
, pp. 366-77
-
-
Van Hoogevest, P.1
Rogue, V.2
Brumec, M.3
-
34
-
-
79952209766
-
Role of phospholipids in the oral and parenteral delivery of poorly water soluble drugs
-
Van Hoogevest P, Liu X, Fahr A, et al. Role of phospholipids in the oral and parenteral delivery of poorly water soluble drugs. J Drug Deliv Sci Technol 2011;21:5-16
-
(2011)
J Drug Deliv Sci Technol
, vol.21
, pp. 5-16
-
-
Van Hoogevest, P.1
Liu, X.2
Fahr, A.3
-
35
-
-
77953404368
-
Nanosuspensions as a drug delivery system: A comprehensive review
-
Shah T, Patel D, Hirani J, et al. Nanosuspensions as a drug delivery system: a comprehensive review. Drug Delivery Technol 2007;7:42-53
-
(2007)
Drug Delivery Technol
, vol.7
, pp. 42-53
-
-
Shah, T.1
Patel, D.2
Hirani, J.3
-
36
-
-
79151476729
-
Universal wet-milling technique to prepare oral nanosuspensions focused on discovery and pre-clinical animal studies. Development of particle design method
-
Niwa T, Miura S, Danjo K. Universal wet-milling technique to prepare oral nanosuspensions focused on discovery and pre-clinical animal studies. Development of particle design method. Int J Pharm 2011;405:218-27
-
(2011)
Int J Pharm
, vol.405
, pp. 218-27
-
-
Niwa, T.1
Miura, S.2
Danjo, K.3
-
37
-
-
0036234785
-
Intravenous administration of poorly soluble new drug entities in early drug discovery: The potential impact of formulation on pharmacokinetic parameters
-
Bittner B, Mountfield RJ. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Curr Opin Drug Discov Devel 2002;5:59-71 (Pubitemid 34453243)
-
(2002)
Current Opinion in Drug Discovery and Development
, vol.5
, Issue.1
, pp. 59-71
-
-
Bittner, B.1
Mountfield, R.J.2
-
38
-
-
0028948839
-
A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability
-
Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-20
-
(1995)
Pharm Res
, vol.12
, pp. 413-20
-
-
Amidon, G.L.1
Lennernas, H.2
Shah, V.P.3
-
39
-
-
78049495059
-
The developability classification system: Application of biopharmaceutics concepts to formulation development
-
Butler JM, Dressman JB. The developability classification system: application of biopharmaceutics concepts to formulation development. J Pharm Sci 2010;99:4940-54
-
(2010)
J Pharm Sci
, vol.99
, pp. 4940-54
-
-
Butler, J.M.1
Dressman, J.B.2
-
41
-
-
0030793250
-
The biopharmaceutic drug classification and drugs administered in extended release (ER) formulations
-
Corrigan OI. The biopharmaceutics drug classification and drugs administered in extended release (ER) formulations. Adv Exp Med Biol 1997;423:111-28 (Pubitemid 27347196)
-
(1997)
Advances in Experimental Medicine and Biology
, vol.423
, pp. 111-128
-
-
Corrigan, O.I.1
-
42
-
-
0031913402
-
Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms
-
DOI 10.1023/A:1011984216775
-
Dressman JB, Amidon GL, Reppas C, et al. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 1998;15:11-22 (Pubitemid 28080861)
-
(1998)
Pharmaceutical Research
, vol.15
, Issue.1
, pp. 11-22
-
-
Dressman, J.B.1
Amidon, G.L.2
Reppas, C.3
Shah, V.P.4
-
43
-
-
0033452575
-
Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data
-
Nicolaides E, Galia E, Efthymiopoulos C, et al. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm Res 1999;16:1876-82 (Pubitemid 30040705)
-
(1999)
Pharmaceutical Research
, vol.16
, Issue.12
, pp. 1876-1882
-
-
Nicolaides, E.1
Galia, E.2
Efthymiopoulos, C.3
Dressman, J.B.4
Reppas, C.5
-
44
-
-
0034080127
-
Dissolution testing as a prognostic tool for oral drug absorption: Dissolution behavior of glibenclamide
-
DOI 10.1023/A:1007529020774
-
Lobenberg R, Kramer J, Shah VP, et al. Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharm Res 2000;17:439-44 (Pubitemid 30395299)
-
(2000)
Pharmaceutical Research
, vol.17
, Issue.4
, pp. 439-444
-
-
Lobenberg, R.1
Kramer, J.2
Shah, V.P.3
Amidon, G.L.4
Dressman, J.B.5
-
45
-
-
0033805179
-
In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs
-
Dressman JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci 2000;11(Suppl 2):S73-80
-
(2000)
Eur J Pharm Sci
, vol.11
, Issue.SUPPL. 2
-
-
Dressman, J.B.1
Reppas, C.2
-
46
-
-
78649714856
-
Study of a standardized taurocholate-lecithin powder for preparing the biorelevant media FeSSIF and FaSSIF dissolution technologies
-
Kloefer B, Van Hoogevest P, Moloney R, et al. Study of a standardized taurocholate-lecithin powder for preparing the biorelevant media FeSSIF and FaSSIF dissolution technologies. Dissol Technol 2010;17:6-13
-
(2010)
Dissol Technol
, vol.17
, pp. 6-13
-
-
Kloefer, B.1
Van Hoogevest, P.2
Moloney, R.3
-
47
-
-
79957861493
-
Nanosizing for oral and parenteral drug delivery: A perspective on formulating poorly-water soluble compounds using wet media milling technology
-
Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev 2011;63:427-40
-
(2011)
Adv Drug Deliv Rev
, vol.63
, pp. 427-40
-
-
Merisko-Liversidge, E.1
Liversidge, G.G.2
-
48
-
-
79551516513
-
Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles
-
Juenemann D, Jantratid E, Wagner C, et al. Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles. Eur J Pharm Biopharm 2011;77:257-64
-
(2011)
Eur J Pharm Biopharm
, vol.77
, pp. 257-64
-
-
Juenemann, D.1
Jantratid, E.2
Wagner, C.3
-
49
-
-
0028824401
-
Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats
-
Liversidge GG, Conzentino P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm 1995;125:309-13
-
(1995)
Int J Pharm
, vol.125
, pp. 309-13
-
-
Liversidge, G.G.1
Conzentino, P.2
-
50
-
-
77955656443
-
Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans
-
Shono Y, Jantratid E, Kesisoglou F, et al. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. Eur J Pharm Biopharm 2010;76:95-104
-
(2010)
Eur J Pharm Biopharm
, vol.76
, pp. 95-104
-
-
Shono, Y.1
Jantratid, E.2
Kesisoglou, F.3
-
52
-
-
35348987129
-
Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations
-
DOI 10.1002/jps.20906
-
Guzman HR, Tawa M, Zhang Z, et al. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci 2007;96:2686-702 (Pubitemid 47597818)
-
(2007)
Journal of Pharmaceutical Sciences
, vol.96
, Issue.10
, pp. 2686-2702
-
-
Guzman, H.R.1
Tawa, M.2
Zhang, Z.3
Ratanabanangkoon, P.4
Shaw, P.5
Gardner, C.R.6
Chen, H.7
Moreau, J.-P.8
Almarsson, O.9
Remenar, J.F.10
-
53
-
-
33750089277
-
Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base
-
DOI 10.1016/j.ejpb.2006.05.008, PII S0939641106001408
-
Hecq J, Deleers M, Fanara D, et al. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb- 35440-3, a highly dosed poorly water-soluble weak base. Eur J Pharm Biopharm 2006;64:360-8 (Pubitemid 44585201)
-
(2006)
European Journal of Pharmaceutics and Biopharmaceutics
, vol.64
, Issue.3
, pp. 360-368
-
-
Hecq, J.1
Deleers, M.2
Fanara, D.3
Vranckx, H.4
Boulanger, P.5
Le Lamer, S.6
Amighi, K.7
-
54
-
-
80054816280
-
Salt screening and selection: New challenges and considerations in the modern pharmaceutical research and development paradigm
-
Qiu Y Chen Y Zhang GGZ Liu L Porter WR. Editors Academic Press, Burlington, London, San Diego, New York
-
Tong WT. Salt screening and selection: new challenges and considerations in the modern pharmaceutical research and development paradigm In: Qiu Y, Chen Y, Zhang GGZ, Liu L, Porter WR. editors. Developing Oral Dosage Forms: pharmaceutical theory and practice. Academic Press; Burlington, London, San Diego, New York; 2009. p. 75-85
-
(2009)
Developing Oral Dosage Forms: Pharmaceutical Theory and Practice
, pp. 75-85
-
-
Tong, W.T.1
-
55
-
-
77956879551
-
High-throughput cocrystal slurry screening by use of in situ Raman microscopy and multi-well plate
-
Kojima T, Tsutsumi S, Yamamoto K, et al. High-throughput cocrystal slurry screening by use of in situ Raman microscopy and multi-well plate. Int J Pharm 2010;399:52-9
-
(2010)
Int J Pharm
, vol.399
, pp. 52-9
-
-
Kojima, T.1
Tsutsumi, S.2
Yamamoto, K.3
-
57
-
-
0030031766
-
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
-
Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100-4
-
(1996)
Cancer Res
, vol.56
, pp. 100-4
-
-
Buchdunger, E.1
Zimmermann, J.2
Mett, H.3
-
58
-
-
1642494654
-
Absolute Bioavailability of Imatinib (Glivec®) Orally versus Intravenous Infusion
-
DOI 10.1177/0091270003262101
-
Peng B, Dutreix C, Mehring G, et al. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 2004;44:158-62 (Pubitemid 38114314)
-
(2004)
Journal of Clinical Pharmacology
, vol.44
, Issue.2
, pp. 158-162
-
-
Peng, B.1
Dutreix, C.2
Mehring, G.3
Hayes, M.J.4
Ben-Am, M.5
Seiberling, M.6
Pokorny, R.7
Cupdeville, R.8
Lloyd, P.9
-
62
-
-
70350776969
-
Nanoparticle Albumin-Bound (NAB) technology is a promising method for anti-cancer drug delivery
-
Fu Q, Sun J, Zhang W, et al. Nanoparticle Albumin-Bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Patents Anticancer Drug Discov 2009;4:262-72
-
(2009)
Recent Patents Anticancer Drug Discov
, vol.4
, pp. 262-72
-
-
Fu, Q.1
Sun, J.2
Zhang, W.3
-
63
-
-
0004307465
-
-
Sterling Drug Inc. assignee US
-
Liversidge GG, Cundy KC, Bishop JF, et al. inventors; Sterling Drug, Inc., assignee. Surface modified drug nanoparticles. US 5,145,684: 1992
-
(1992)
Surface Modified Drug Nanoparticles
, vol.5
, Issue.145
, pp. 684
-
-
Liversidge, G.G.1
Cundy, K.C.2
Bishop, J.F.3
-
65
-
-
77957255549
-
Accelerated formulation development for nanomilled active pharmaceutical ingredients using a screening approach chemical engineering & technology
-
Juhnke M, Berghausen J, Timpe C. Accelerated formulation development for nanomilled active pharmaceutical ingredients using a screening approach chemical engineering & technology. Chem Eng Technol 2010;33:1412-18
-
(2010)
Chem Eng Technol
, vol.33
, pp. 1412-18
-
-
Juhnke, M.1
Berghausen, J.2
Timpe, C.3
-
66
-
-
78649737917
-
Nano-suspension technology: A review
-
Lakshmi P, Kumar GH. Nano-suspension technology: a review. Int J Pharm Pharm 2010;2:35-40
-
(2010)
Int J Pharm Pharm
, vol.2
, pp. 35-40
-
-
Lakshmi, P.1
Kumar, G.H.2
-
67
-
-
34548134519
-
Cyclodextrins as pharmaceutical solubilizers
-
DOI 10.1016/j.addr.2007.05.012, PII S0169409X07000841
-
Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 2007;59:645-66 (Pubitemid 47299263)
-
(2007)
Advanced Drug Delivery Reviews
, vol.59
, Issue.7
, pp. 645-666
-
-
Brewster, M.E.1
Loftsson, T.2
-
68
-
-
84857658288
-
-
Cydex Pharmaceuticals. Inc
-
Cydex Pharmaceuticals, Inc.: Marketed products. Available from: http://cydexpharma.com/approvedproducts.html
-
Marketed Products
-
-
-
72
-
-
80054799174
-
-
CyDex Pharmaceuticals, Inc., assignee US 7,635,773
-
Antle V. inventor, CyDex Pharmaceuticals, Inc., assignee. Sulfoalkyl ether cyclodextrin compositions. US 7,635,773: 2009
-
(2009)
Sulfoalkyl Ether Cyclodextrin Compositions
-
-
Antle, V.1
-
73
-
-
80054814101
-
-
US 7,563,935
-
Leigh S, Leigh MLS, Van Hoogevest P. inventors; Phares Pharmaceutical Research N.V., assignee. Crystal forms of astaxanthin. US 7,563,935: 2009
-
(2009)
Phares Pharmaceutical Research N.V. Assignee. Crystal Forms of Astaxanthin
-
-
Leigh, S.1
Mls, L.2
Van Hoogevest, P.3
-
75
-
-
77955468413
-
Phospholipids and lipid-based formulations in oral drug delivery
-
Fricker G, Kromp T, Wendel A, et al. Phospholipids and lipid-based formulations in oral drug delivery. Pharm Res 2010;27:1469-86
-
(2010)
Pharm Res
, vol.27
, pp. 1469-86
-
-
Fricker, G.1
Kromp, T.2
Wendel, A.3
-
76
-
-
78049499869
-
New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs
-
Mullertz A, Ogbonna A, Ren S, et al. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J Pharm Pharmacol 2010; In press
-
(2010)
J Pharm Pharmacol
-
-
Mullertz, A.1
Ogbonna, A.2
Ren, S.3
-
77
-
-
79952224749
-
Oral self-emulsifyng drug delivery sytems, from biopharmaceutical to technical formulation aspects
-
Kuentz M. Oral self-emulsifyng drug delivery sytems, from biopharmaceutical to technical formulation aspects. J Drug Deliv Sci Technol 2011;21:17-20
-
(2011)
J Drug Deliv Sci Technol
, vol.21
, pp. 17-20
-
-
Kuentz, M.1
-
78
-
-
80054799364
-
A review : self emulsifying drug delivery system
-
Mistry RB, Sheth NS. A review : self emulsifying drug delivery system. Int J Pharm Pharm Sci 2011;3:23-8
-
(2011)
Int J Pharm Pharm Sci
, vol.3
, pp. 23-8
-
-
Mistry, R.B.1
Sheth, N.S.2
-
79
-
-
10444279209
-
Cyclodextrin-based pharmaceutics: Past, present and future
-
DOI 10.1038/nrd1576
-
Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 2004;3:1023-35 (Pubitemid 39642365)
-
(2004)
Nature Reviews Drug Discovery
, vol.3
, Issue.12
, pp. 1023-1035
-
-
Davis, M.E.1
Brewster, M.E.2
-
80
-
-
21844459973
-
2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): A toxicology review
-
DOI 10.1016/j.fct.2005.03.007, PII S0278691505001006
-
Gould S, Scott RC. 2-Hydroxypropylbeta- cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol 2005;43:1451-9 (Pubitemid 40961909)
-
(2005)
Food and Chemical Toxicology
, vol.43
, Issue.10
, pp. 1451-1459
-
-
Gould, S.1
Scott, R.C.2
-
81
-
-
85015640989
-
Melt-Extruded Molecular Dispersions
-
Ghebre Sellassie I Martin C. editors Marcel Dekker, New York
-
Breitenbach J, Magerlein M. Melt-Extruded Molecular Dispersions. In: Ghebre Sellassie I, Martin C. editors. Pharmaceutical extrusion technology. Marcel Dekker; New York, 2003. p. 245-60
-
(2003)
Pharmaceutical Extrusion Technology
, pp. 245-60
-
-
Breitenbach, J.1
Magerlein, M.2
-
82
-
-
0015124656
-
Pharmaceutical applications of solid dispersion systems
-
Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci 1971;60:1281-302
-
(1971)
J Pharm Sci
, vol.60
, pp. 1281-302
-
-
Chiou, W.L.1
Riegelman, S.2
-
83
-
-
34447296485
-
Stabilization of hot-melt extrusion formulations containing solid solutions using polymer blends
-
DOI 10.1208/pt0802027, 50
-
Prodduturi S, Urman KL, Otaigbe JU, et al. Stabilization of hot-melt extrusion formulations containing solid solutions using polymer blends. AAPS PharmSciTech 2007;8:E1-10 (Pubitemid 47053749)
-
(2007)
AAPS PharmSciTech
, vol.8
, Issue.2
-
-
Prodduturi, S.1
Urman, K.L.2
Otaigbe, J.U.3
Repka, M.A.4
-
84
-
-
75749094421
-
Review: Physical chemistry of solid dispersions
-
Janssens S, Van den Mooter G. Review: physical chemistry of solid dispersions. J Pharm Pharmacol 2009;61:1571-86
-
(2009)
J Pharm Pharmacol
, vol.61
, pp. 1571-86
-
-
Janssens, S.1
Van Den Mooter, G.2
-
85
-
-
84857648607
-
-
Sporanox product. Available from: http://www.rxlist.com/sporanox-drug.htm
-
Sporanox Product
-
-
-
86
-
-
84857656148
-
-
Intelence product. Available from: http://www.rxlist.com/intelence-drug. htm
-
Intelence Product
-
-
-
87
-
-
84857652797
-
-
Prograf product. Available from: http://www.rxlist.com/prograf-drug.htm
-
Prograf Product
-
-
-
88
-
-
84857644437
-
-
Crestor product. Available from: http://www.rxlist.com/crestor-drug.htm
-
Crestor Product
-
-
-
89
-
-
84857658825
-
-
Gris-PEG product. Available from: http://www.rxlist.com/gris-peg-drug.htm
-
Gris-PEG Product
-
-
-
90
-
-
0020471096
-
Effect of food on the bioavailability of griseofulvin from microsize and PEG ultramicrosize (GRIS-PEG®) plain tablets
-
Aoyagi N, Ogata H, Kaniwa N, et al. Effect of food on the bioavailability of griseofulvin from microsize and PEG ultramicrosize (GRIS-PEG) plain tablets. J Pharmacobiodyn 1982;5:120-4 (Pubitemid 12121224)
-
(1982)
Journal of Pharmacobio-Dynamics
, vol.5
, Issue.2
, pp. 120-124
-
-
Aoyagi, N.1
Ogata, H.2
Kaniwa, N.3
Ejima, A.4
-
91
-
-
84857646976
-
-
Kaletra product. Available from: http://www.rxlist.com/kaletra-tablets- drug.htm
-
Kaletra Product
-
-
-
92
-
-
84857656156
-
-
Rapamune product. Available from: http://www.rxlist.com/rapamune-drug.htm
-
Rapamune Product
-
-
-
93
-
-
84857652762
-
-
Emend oral product. Available from: http://www.rxlist.com/emend-drug.htm
-
Emend Oral Product
-
-
-
94
-
-
20844446627
-
The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: A Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human
-
DOI 10.1016/j.ijpharm.2004.08.001, PII S0378517304004831
-
Wu Y, Loper A, Landis E, et al. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm 2004;285:135-46 (Pubitemid 39361543)
-
(2004)
International Journal of Pharmaceutics
, vol.285
, Issue.1-2
, pp. 135-146
-
-
Wu, Y.1
Loper, A.2
Landis, E.3
Hettrick, L.4
Novak, L.5
Lynn, K.6
Chen, C.7
Thompson, K.8
Higgins, R.9
Batra, U.10
Shelukar, S.11
Kwei, G.12
Storey, D.13
-
95
-
-
84857642902
-
-
Megace ES product. Available from: http://www.rxlist.com/megace-es-drug. htm
-
Megace ES Product
-
-
-
96
-
-
84857652002
-
-
Megace ES product UK. Available from: http://www.medicines.org.uk/EMC/ medicine/346/SPC/Megace+160+mg +Tablets/
-
Megace ES Product UK
-
-
-
97
-
-
77952497288
-
Food effect on the bioavailability of two distinct formulations of megestrol acetate oral suspension
-
Deschamps B, Musaji N, Gillespie JA. Food effect on the bioavailability of two distinct formulations of megestrol acetate oral suspension. Int J Nanomedicine 2009;4:185-92
-
(2009)
Int J Nanomedicine
, vol.4
, pp. 185-92
-
-
Deschamps, B.1
Musaji, N.2
Gillespie, J.A.3
-
98
-
-
66149129222
-
Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer
-
Miele E, Spinelli GP, Tomao F, et al. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine 2009;4:99-105
-
(2009)
Int J Nanomedicine
, vol.4
, pp. 99-105
-
-
Miele, E.1
Spinelli, G.P.2
Tomao, F.3
-
99
-
-
30444457035
-
Case report: Abraxane in the treatment of ovarian cancer: The absence of hypersensitivity reactions
-
Micha JP, Goldstein BH, Birk CL, et al. Case report: Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol 2006;100:437-43
-
(2006)
Gynecol Oncol
, vol.100
, pp. 437-43
-
-
Micha, J.P.1
Goldstein, B.H.2
Birk, C.L.3
-
100
-
-
84857652239
-
-
Abraxane product. Available from: http://www.rxlist.com/abraxane-drug.htm
-
Abraxane Product
-
-
-
101
-
-
84857641906
-
-
Albumin product. Available from: http://www.orgyn.com/resources/genrx/ D000114.asp
-
Albumin Product
-
-
-
102
-
-
84857658781
-
-
Invega sustenna product. Available from: http://www.rxlist.com/invega- sustennadrug.htm
-
Invega Sustenna Product
-
-
-
104
-
-
1642397172
-
Lipid-based formulations of amphotericin B
-
DOI 10.1358/dot.2004.40.2.799425
-
Veerareddy PR, Vobalaboina V. Lipid-based formulations of amphotericin B. Drugs Today (Barc) 2004;40:133-45 (Pubitemid 38387618)
-
(2004)
Drugs of Today
, vol.40
, Issue.2
, pp. 133-145
-
-
Veerareddy, P.R.1
Vobalaboina, V.2
-
105
-
-
80054810389
-
-
EMA 2008
-
(2008)
EMA
-
-
-
106
-
-
0003069473
-
An industrial liposomal dosage form for muramyl-tripeptide-phosphatidyl ethanolamine (MTP-PE)
-
Fidler IJ, Lopez-Berestein G. editors Alan R. Liss, Inc, New York
-
Van Hoogevest P, Fankhauser P. An industrial liposomal dosage form for muramyl-tripeptide-phosphatidyl ethanolamine (MTP-PE). In: Fidler IJ, Lopez-Berestein G. editors. Liposomes in the therapy of infectious diseases and cancer. Alan R. Liss, Inc; New York 1989. p. 453
-
(1989)
Liposomes in the Therapy of Infectious Diseases and Cancer
, pp. 453
-
-
Van Hoogevest, P.1
Fankhauser, P.2
-
107
-
-
0021930709
-
Increased adherence of sickled and phosphatidylserine-enriched human erythrocytes to cultured human peripheral blood monocytes
-
Schwartz RS, Tanaka Y, Fidler IJ, et al. Increased adherence of sickled and phosphatidylserine-enriched human erythrocytes to cultured human peripheral blood monocytes. J Clin Invest 1985;75:1965-72 (Pubitemid 15233585)
-
(1985)
Journal of Clinical Investigation
, vol.75
, Issue.6
, pp. 1965-1972
-
-
Schwartz, R.S.1
Tanaka, Y.2
Fidler, I.J.3
-
108
-
-
0012694409
-
Comparison of free and liposomal MTP-PE. Pharmacological and toxicological aspects
-
Fidler IJ Lopez-Berestein G. editors Alan R. Liss Inc; New York
-
Schumann G, van Hoogevest P, Fankhauser P, et al.Comparison of free and liposomal MTP-PE. Pharmacological and toxicological aspects. In: Fidler IJ, Lopez-Berestein G. editors. Liposomes in the therapy of infectious diseases and cancer. Alan R. Liss, Inc; New York; 1989. p. 191
-
(1989)
Liposomes in the Therapy of Infectious Diseases and Cancer
, pp. 191
-
-
Schumann, G.1
Van Hoogevest, P.2
Fankhauser, P.3
-
110
-
-
84857650568
-
-
Visudyne product. Available from: www. visudyne.com
-
Visudyne Product
-
-
-
113
-
-
0025707612
-
Biodistribution of tritiated benzoporphyrin derivative (3HBPD- MA), a new potent photosensitizer, in normal and tumor-bearing mice
-
Richter AM, Cerruti-Sola S, Sternberg ED, et al. Biodistribution of tritiated benzoporphyrin derivative (3HBPD- MA), a new potent photosensitizer, in normal and tumor-bearing mice. J Photochem Photobiol B 1990;5:231-44
-
(1990)
J Photochem Photobiol B
, vol.5
, pp. 231-44
-
-
Richter, A.M.1
Cerruti-Sola, S.2
Sternberg, E.D.3
-
115
-
-
84857645315
-
-
Definity product. Available from: http://www.rxlist.com/definity-drug.htm
-
Definity Product
-
-
-
118
-
-
80054824342
-
A FDA perspective on nanomedicine: Current initiatives in the US
-
Pena C. A FDA perspective on nanomedicine: current initiatives in the US. In: Commisioner Oot; 2010
-
(2010)
Commisioner Oot
-
-
Pena, C.1
-
119
-
-
80054825577
-
Manual of policies and procedures MAPP5015.9. Reporting format in nanotechnology information in CMC review 6/3/2010
-
Manual of policies and procedures MAPP5015.9. Reporting format in nanotechnology information in CMC review 6/3/2010. In: Science CodearOop; 2010
-
(2010)
Science CodearOop
-
-
-
120
-
-
79953251219
-
Self-assembly of cyclodextrins: The effect of the guest molecule
-
Messner M, Kurkov SV, Flavia-Piera R, et al. Self-assembly of cyclodextrins: the effect of the guest molecule. Int J Pharm 2011;408:235-47
-
(2011)
Int J Pharm
, vol.408
, pp. 235-47
-
-
Messner, M.1
Kurkov, S.V.2
Flavia-Piera, R.3
-
121
-
-
79952314729
-
Self-assembly of cyclodextrin complexes: Aggregation of hydrocortisone/cyclodextrin complexes
-
Messner M, Kurkov SV, Brewster ME, et al. Self-assembly of cyclodextrin complexes: aggregation of hydrocortisone/cyclodextrin complexes. Int J Pharm 2011;407:174-83
-
(2011)
Int J Pharm
, vol.407
, pp. 174-83
-
-
Messner, M.1
Kurkov, S.V.2
Brewster, M.E.3
-
122
-
-
77951210910
-
Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation
-
Van't Klooster G, Hoeben E, Borghys H, et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother 2010 54: 2042-50
-
(2010)
Antimicrob Agents Chemother
, vol.54
, pp. 2042-2050
-
-
Van't Klooster, G.1
Hoeben, E.2
Borghys, H.3
-
123
-
-
0036181889
-
Practical aspects of lyophilization using non-aqueous co-solvent systems
-
DOI 10.1016/S0928-0987(01)00221-4, PII S0928098701002214
-
Teagarden DL, Baker DS. Practical aspects of lyophilization using non-aqueous co-solvent systems. Eur J Pharm Sci 2002;15:115-33 (Pubitemid 34155373)
-
(2002)
European Journal of Pharmaceutical Sciences
, vol.15
, Issue.2
, pp. 115-133
-
-
Teagarden, D.L.1
Baker, D.S.2
|